AI Drug Discovery Accelerates, but Testing Phase Remains a Costly Bottleneck
The integration of artificial intelligence into pharmaceutical research is dramatically accelerating the early stages of drug discovery. AI models can now analyze vast datasets to identify promising drug candidates and predict their efficacy at an unprecedented pace. However, this acceleration at the front end of development is creating a paradox: